NEW YORK (GenomeWeb) – Becton Dickinson said today that it has licensed its patented stochastic labelling technology for multiple commercial applications to Roche on a non-exclusive basis.

Specific financial terms of the agreement were not disclosed.

BD's patented stochastic labelling technology incorporates molecular indexes, also called UMIs or molecular barcodes. The technology enables precise counting of individual biological molecules, including DNA or RNA, in complex and often volume-limited samples, BD said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.